US20030119185A1
(en)
*
|
2000-02-24 |
2003-06-26 |
Xcyte Therapies, Inc. |
Activation and expansion of cells
|
US7541184B2
(en)
*
|
2000-02-24 |
2009-06-02 |
Invitrogen Corporation |
Activation and expansion of cells
|
US20030235908A1
(en)
*
|
2000-02-24 |
2003-12-25 |
Xcyte Therapies, Inc. |
Activation and expansion of cells
|
US20070154399A1
(en)
*
|
2000-10-27 |
2007-07-05 |
Hadden John W |
Immunotherapy for immune suppressed patients
|
US20070025958A1
(en)
|
2000-10-27 |
2007-02-01 |
Hadden John W |
Vaccine immunotherapy
|
CA2464228C
(en)
|
2000-10-27 |
2017-01-17 |
Immuno-Rx, Inc. |
Vaccine immunotherapy for immune suppressed patients
|
WO2002040069A2
(en)
*
|
2000-11-06 |
2002-05-23 |
Shibuya Terry Y |
Bioactive surgical suture
|
ATE529097T1
(de)
*
|
2000-12-07 |
2011-11-15 |
Nycomed Gmbh |
Pharmazeutische zubereitung in form einer paste mit einem säurelabilen wirkstoff
|
US20040191246A1
(en)
|
2003-02-26 |
2004-09-30 |
Connelly Patrick R. |
Process for in vivo treatment of specific biological targets in bodily fluid
|
US7670781B2
(en)
*
|
2002-01-03 |
2010-03-02 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of T-cells using an agent that provides a primary activation signal and another agent that provides a co-stimulatory signal
|
US7638326B2
(en)
|
2002-01-03 |
2009-12-29 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of T-cells using an engineered multivalent signaling platform
|
US7745140B2
(en)
|
2002-01-03 |
2010-06-29 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
|
AU2003216436A1
(en)
*
|
2002-02-08 |
2003-09-02 |
Life Technologies Corporation |
Compositions and methods for restoring immune responsiveness in patients with immunological defects
|
CN100379852C
(zh)
*
|
2002-02-08 |
2008-04-09 |
埃克斯西特治疗公司 |
用于在免疫缺陷患者体内恢复免疫响应的组合物和方法
|
DE10212108A1
(de)
*
|
2002-03-13 |
2003-10-02 |
Tegenero Ag |
Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung
|
DE60335253D1
(de)
|
2002-03-25 |
2011-01-20 |
Takara Bio Inc |
Verfahren zur produktion eines zytotoxischen lymphozyten
|
US20050084967A1
(en)
|
2002-06-28 |
2005-04-21 |
Xcyte Therapies, Inc. |
Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
|
AU2003253684A1
(en)
*
|
2002-06-28 |
2004-01-19 |
Xcyte Therapies, Inc. |
Compositions and methods for restoring immune repertoire in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
|
DE10230223A1
(de)
*
|
2002-07-04 |
2004-01-22 |
Tegenero Ag |
Mikropartikel mit CD28-spezifischen monoklonalen Antikörpern
|
EP1581637A4
(en)
*
|
2002-11-07 |
2007-04-25 |
Univ Chicago |
MATERIALS AND METHODS WITH HUMAN STEM CELLS
|
CN1230531C
(zh)
*
|
2002-12-09 |
2005-12-07 |
清华大学 |
从样品中分离细胞粒子的方法
|
CA2525519A1
(en)
*
|
2003-05-08 |
2004-12-02 |
Xcyte Therapies, Inc. |
Generation and isolation of antigen-specific t cells
|
US7435592B2
(en)
*
|
2003-05-13 |
2008-10-14 |
Immunovative Therapies, Ltd. |
Compositions for allogeneic cell therapy
|
US20110142887A1
(en)
*
|
2009-12-15 |
2011-06-16 |
Immunovative Therapies Ltd. |
Methods and compositions for liquidation of tumors
|
US20070025961A1
(en)
|
2003-06-03 |
2007-02-01 |
Kenzo Bamba |
Composition for stabilizing survival of transplanted hematopoietic stem cell, kit for obtaining the composition, method of stabilizing survival of transplanted hematopoietic stem cell, human monoclonal antibody or human polyclonal antibody and method of producing the same, gene encoding human monoclonal antibody and transf
|
AU2004267313B2
(en)
|
2003-08-22 |
2009-09-24 |
Takara Bio Inc. |
Process for producing cytotoxic lymphocytes
|
EP1663308A1
(en)
*
|
2003-09-22 |
2006-06-07 |
Xcyte Therapies, Inc |
Compositions and methods to accelerate hematologic recovery
|
KR101111231B1
(ko)
*
|
2003-09-25 |
2012-02-17 |
비바리스 |
마이크로 웰 어레이 칩 및 그 제조방법
|
US8465453B2
(en)
*
|
2003-12-03 |
2013-06-18 |
Mayo Foundation For Medical Education And Research |
Kits, apparatus and methods for magnetically coating medical devices with living cells
|
US20090118817A1
(en)
*
|
2005-06-16 |
2009-05-07 |
Mayo Foundation For Medical Education And Research |
Magnetic Medical Apparatus, Kits, and Methods
|
JP2007538000A
(ja)
*
|
2004-01-08 |
2007-12-27 |
リージエンツ・オブ・ザ・ユニバーシテイ・オブ・カリフオルニア |
制御性t細胞は自己免疫を抑制する
|
US7592431B2
(en)
*
|
2004-02-26 |
2009-09-22 |
Immunovative Therapies, Ltd. |
Biodegradable T-cell Activation device
|
US7678572B2
(en)
|
2004-02-26 |
2010-03-16 |
Immunovative Therapies, Ltd. |
Methods for preparing T-cells for cell therapy
|
CA2568344C
(en)
|
2004-05-27 |
2016-01-19 |
The Trustees Of The University Of Pennsylvania |
Novel artificial antigen presenting cells and uses therefor
|
CN105233349B
(zh)
|
2005-07-15 |
2019-06-18 |
胶束技术股份有限公司 |
包含受控形态的药物粉末的聚合物涂层
|
CN101243187B
(zh)
*
|
2005-08-17 |
2012-07-11 |
宝生物工程株式会社 |
淋巴细胞的制备方法
|
KR101138868B1
(ko)
|
2005-08-23 |
2012-05-14 |
삼성전자주식회사 |
생분자의 다이일렉트릭 특성을 나노입자로 향상시켜표적생분자만을 선택적으로 분리하는 dep 및 나노입자를이용한 표적생분자분리방법
|
US9388382B2
(en)
|
2005-10-05 |
2016-07-12 |
The Board Of Trustees Of The University Of Illinois |
Isolation of CD14 negative, CD45 positive and CD117 positive embryonic-like stem cells free of monocytes from human umbilical cord blood mononuclear cells
|
PL2019657T3
(pl)
|
2006-04-26 |
2015-10-30 |
Micell Technologies Inc |
Powłoki zawierające wiele leków
|
US20100233192A1
(en)
*
|
2006-08-23 |
2010-09-16 |
Binex Co., Ltd. |
Manufacturing Method of Activated Lymphocytes for Immunotherapy
|
US20090181078A1
(en)
|
2006-09-26 |
2009-07-16 |
Infectious Disease Research Institute |
Vaccine composition containing synthetic adjuvant
|
US8835163B2
(en)
|
2006-10-18 |
2014-09-16 |
The Board Of Trustees Of The University Of Illinois |
Embryonic-like stem cells derived from adult human peripheral blood and methods of use
|
ES2629086T3
(es)
*
|
2006-10-30 |
2017-08-07 |
Genomix Co., Ltd. |
Sustancia farmacéutica para promover la regeneración funcional de tejido dañado
|
US11426494B2
(en)
*
|
2007-01-08 |
2022-08-30 |
MT Acquisition Holdings LLC |
Stents having biodegradable layers
|
US20090062237A1
(en)
*
|
2007-06-15 |
2009-03-05 |
Mayo Foundation For Medical Education And Research |
Evaluating immune competence
|
US7816135B2
(en)
*
|
2007-07-05 |
2010-10-19 |
Becton, Dickinson And Company |
Method of analyzing lymphocytes
|
WO2009070639A1
(en)
|
2007-11-28 |
2009-06-04 |
Irx Therapeutics, Inc. |
Method of increasing immunological effect
|
US20090259251A1
(en)
*
|
2008-04-11 |
2009-10-15 |
Cohen Matthew D |
Loop suture
|
WO2009137238A2
(en)
*
|
2008-04-14 |
2009-11-12 |
Irx Therapeutics, Inc. |
Irx-2 modified manufacturing process
|
CA2722909A1
(en)
*
|
2008-04-30 |
2009-11-05 |
Genomix Co., Ltd. |
Method for collecting functional cells in vivo with high efficiency
|
JP5814549B2
(ja)
*
|
2008-04-30 |
2015-11-17 |
株式会社ジェノミックス |
損傷組織の機能的再生促進医薬
|
CN102076350A
(zh)
*
|
2008-04-30 |
2011-05-25 |
吉诺米克斯股份有限公司 |
将骨髓来源的多能干细胞动员到末梢循环的药物
|
DK2429585T3
(en)
|
2009-05-15 |
2018-07-30 |
Irx Therapeutics Inc |
VACCINE IMMUNOTHERAPY
|
AU2010259858A1
(en)
*
|
2009-06-11 |
2012-02-02 |
Bamdad, Cynthia C. |
Methods for culturing stem and progenitor cells
|
CA2776613A1
(en)
|
2009-10-07 |
2011-04-14 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Educatio N |
Devices, systems and methods for cell modification
|
US11191786B2
(en)
|
2009-10-28 |
2021-12-07 |
StemRIM Inc. |
Agents for promoting tissue regeneration by recruiting bone marrow mesenchymal stem cells and/or pluripotent stem cells into blood
|
CA2820202C
(en)
|
2009-12-08 |
2018-06-12 |
Irx Therapeutics, Inc. |
Method of reversing immune suppression of langerhans cells
|
US8968362B2
(en)
|
2010-04-08 |
2015-03-03 |
Covidien Lp |
Coated looped suture
|
EP2601957B1
(en)
*
|
2010-08-06 |
2019-04-10 |
Canine-Lab. Inc. |
Immunological function enhancing agent
|
SG190997A1
(en)
|
2010-12-09 |
2013-07-31 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
CN103442768A
(zh)
|
2011-01-18 |
2013-12-11 |
宾夕法尼亚大学董事会 |
治疗癌的组合物和方法
|
CA2834255C
(en)
|
2011-04-26 |
2021-11-02 |
Genomix Co., Ltd. |
Peptide for inducing regeneration of tissue and use thereof
|
CA2838041C
(en)
|
2011-05-03 |
2018-09-25 |
Immunovative Therapies, Ltd. |
Methods for handling biological drugs containing living cells
|
CN109876138A
(zh)
|
2011-05-03 |
2019-06-14 |
免疫创新治疗有限公司 |
利用免疫疗法诱导il-12
|
RU2018107763A
(ru)
*
|
2011-06-29 |
2019-02-25 |
Селлестис Лимитед |
Способ анализа клеточно-опосредованного иммунного ответа с повышенной чувствительностью
|
WO2013036585A1
(en)
*
|
2011-09-06 |
2013-03-14 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of t cell subsets using biocompatible solid substrates with tunable rigidity
|
JP2014526251A
(ja)
*
|
2011-09-07 |
2014-10-06 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
流体サンプルから回収された標的細胞の数を増大させる方法
|
US10421960B2
(en)
|
2011-09-16 |
2019-09-24 |
The Trustees Of The University Of Pennsylvania |
RNA engineered T cells for the treatment of cancer
|
WO2013044225A1
(en)
|
2011-09-22 |
2013-03-28 |
The Trustees Of The University Of Pennsylvania |
A universal immune receptor expressed by t cells for the targeting of diverse and multiple antigens
|
WO2013063419A2
(en)
|
2011-10-28 |
2013-05-02 |
The Trustees Of The University Of Pennsylvania |
A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
|
US9422351B2
(en)
|
2011-11-03 |
2016-08-23 |
The Trustees Of The University Of Pennsylvania |
Isolated B7-H4 specific compositions and methods of use thereof
|
WO2013070468A1
(en)
|
2011-11-08 |
2013-05-16 |
The Trustees Of The University Of Pennsylvania |
Glypican-3-specific antibody and uses thereof
|
JP2015509716A
(ja)
|
2012-02-22 |
2015-04-02 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
第二世代キメラ抗原受容体におけるcd2シグナル伝達ドメインの使用
|
WO2013126712A1
(en)
|
2012-02-22 |
2013-08-29 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
|
WO2013126733A1
(en)
|
2012-02-22 |
2013-08-29 |
The Trustees Of University Of Pennsylvania |
Use of icos-based cars to enhance antitumor activity and car persistence
|
ES2962571T3
(es)
*
|
2012-05-25 |
2024-03-19 |
Cellectis |
Métodos para modificar células T alogénicas y resistentes a la inmunosupresión para inmunoterapia
|
US20150017136A1
(en)
|
2013-07-15 |
2015-01-15 |
Cellectis |
Methods for engineering allogeneic and highly active t cell for immunotherapy
|
CN102718869B
(zh)
*
|
2012-06-06 |
2014-08-06 |
西安交通大学 |
一种固定化呈递免疫共刺激分子的微球及其制备方法
|
EA201590208A1
(ru)
|
2012-07-13 |
2015-11-30 |
Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания |
Усиление активности т-клеток car путем совместного введения биспецифического антитела
|
CA2878862C
(en)
|
2012-07-13 |
2023-01-10 |
The Trustees Of The University Of Pennsylvania |
Methods of assessing the suitability of transduced t cells for administration
|
WO2014039513A2
(en)
|
2012-09-04 |
2014-03-13 |
The Trustees Of The University Of Pennsylvania |
Inhibition of diacylglycerol kinase to augment adoptive t cell transfer
|
DK2893004T3
(en)
|
2012-09-04 |
2019-02-04 |
Cellectis |
MULTI-CHAIN CHEMICAL ANTIGEN RECEPTOR AND APPLICATIONS THEREOF
|
EP2711418B1
(en)
|
2012-09-25 |
2017-08-23 |
Miltenyi Biotec GmbH |
Method for polyclonal stimulation of T cells by flexible nanomatrices
|
AR092745A1
(es)
|
2012-10-01 |
2015-04-29 |
Univ Pennsylvania |
Composiciones que comprenden un dominio de union anti-fap y metodos para hacer blanco en celulas estromales para el tratamiento del cancer
|
WO2014055657A1
(en)
|
2012-10-05 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Use of a trans-signaling approach in chimeric antigen receptors
|
WO2014055771A1
(en)
|
2012-10-05 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Human alpha-folate receptor chimeric antigen receptor
|
WO2014065347A1
(ja)
|
2012-10-25 |
2014-05-01 |
株式会社ジェノミックス |
Hmgb1断片を利用した新規心筋梗塞の治療法
|
DK2913059T3
(en)
|
2012-10-25 |
2018-06-25 |
Genomix Co Ltd |
Hitherto UNKNOWN PROCEDURE FOR TREATMENT OF SPINE INJURY USING HMGB1 FRAGMENT
|
AU2013204922B2
(en)
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
CN111139256A
(zh)
|
2013-02-20 |
2020-05-12 |
诺华股份有限公司 |
使用人源化抗EGFRvIII嵌合抗原受体治疗癌症
|
EP3744736A1
(en)
|
2013-02-20 |
2020-12-02 |
Novartis AG |
Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
|
AU2014244119B2
(en)
|
2013-03-14 |
2019-08-15 |
The Johns Hopkins University |
Nanoscale Artificial Antigen Presenting Cells
|
US9446105B2
(en)
|
2013-03-15 |
2016-09-20 |
The Trustees Of The University Of Pennsylvania |
Chimeric antigen receptor specific for folate receptor β
|
JP6493692B2
(ja)
|
2013-03-15 |
2019-04-10 |
セルジーン コーポレイション |
修飾されたtリンパ球
|
US9745368B2
(en)
|
2013-03-15 |
2017-08-29 |
The Trustees Of The University Of Pennsylvania |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
UY35468A
(es)
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
AU2014266833B2
(en)
|
2013-05-13 |
2020-07-02 |
Cellectis |
Methods for engineering highly active T cell for immunotherapy
|
ES2930431T3
(es)
|
2013-05-13 |
2022-12-12 |
Cellectis |
Receptor quimérico de antígeno específico para CD19 y sus usos
|
CA2913830C
(en)
|
2013-05-29 |
2021-06-29 |
Cellectis |
Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
|
US10801070B2
(en)
|
2013-11-25 |
2020-10-13 |
The Broad Institute, Inc. |
Compositions and methods for diagnosing, evaluating and treating cancer
|
US11725237B2
(en)
|
2013-12-05 |
2023-08-15 |
The Broad Institute Inc. |
Polymorphic gene typing and somatic change detection using sequencing data
|
CN105658784B
(zh)
*
|
2013-12-18 |
2018-12-11 |
东洋制罐集团控股株式会社 |
培养容器、淋巴细胞的培养方法、培养容器的制造方法和固相化装置
|
SG11201604815RA
(en)
|
2013-12-19 |
2016-07-28 |
Novartis Ag |
Human mesothelin chimeric antigen receptors and uses thereof
|
WO2015095811A2
(en)
|
2013-12-20 |
2015-06-25 |
The Board Institute Inc. |
Combination therapy with neoantigen vaccine
|
JP6793902B2
(ja)
|
2013-12-20 |
2020-12-02 |
ノバルティス アーゲー |
調節可能キメラ抗原受容体
|
EP4303229A3
(en)
|
2014-01-21 |
2024-04-17 |
Novartis AG |
Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
|
US10836998B2
(en)
|
2014-02-14 |
2020-11-17 |
Cellectis |
Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
|
EP3116902B1
(en)
|
2014-03-11 |
2020-01-01 |
Cellectis |
Method for generating t-cells compatible for allogenic transplantation
|
ES2939760T3
(es)
|
2014-03-15 |
2023-04-26 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico para antígenos
|
ES2857226T3
(es)
|
2014-03-15 |
2021-09-28 |
Novartis Ag |
Receptor de antígeno quimérico regulable
|
TR201910814T4
(tr)
|
2014-03-19 |
2019-08-21 |
Cellectis |
Kanser immünoterapisi için cd123 spesifik kimerik antijen reseptörleri.
|
LT3888674T
(lt)
|
2014-04-07 |
2024-07-25 |
Novartis Ag |
Vėžio gydymas naudojant anti-cd19 chimerinį antigeno receptorių
|
EP3129473B8
(en)
|
2014-04-11 |
2020-12-23 |
Cellectis |
Method for generating immune cells resistant to arginine and/or tryptophan depleted microenvironment
|
KR101988614B1
(ko)
*
|
2014-04-25 |
2019-06-12 |
블루버드 바이오, 인코포레이티드. |
양자 세포 치료제를 제조하는 개선된 방법
|
AU2015249390B2
(en)
|
2014-04-25 |
2019-08-15 |
2Seventy Bio, Inc. |
MND promoter chimeric antigen receptors
|
WO2015168613A2
(en)
|
2014-05-02 |
2015-11-05 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods of chimeric autoantibody receptor t cells
|
AU2015254595B2
(en)
|
2014-05-02 |
2019-06-27 |
Cellectis |
CS1 specific multi-chain chimeric antigen receptor
|
AU2015269197B2
(en)
|
2014-06-06 |
2018-10-04 |
2Seventy Bio, Inc. |
Improved T cell compositions
|
KR102594343B1
(ko)
|
2014-07-21 |
2023-10-26 |
노파르티스 아게 |
Cd33 키메라 항원 수용체를 사용한 암의 치료
|
EP3193915A1
(en)
|
2014-07-21 |
2017-07-26 |
Novartis AG |
Combinations of low, immune enhancing. doses of mtor inhibitors and cars
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
TWI750110B
(zh)
|
2014-07-21 |
2021-12-21 |
瑞士商諾華公司 |
使用人類化抗-bcma嵌合抗原受體治療癌症
|
SG10201900455YA
(en)
|
2014-07-24 |
2019-02-27 |
Bluebird Bio Inc |
Bcma chimeric antigen receptors
|
JP6721568B2
(ja)
|
2014-07-29 |
2020-07-15 |
セレクティスCellectis |
がん免疫療法のためのror1(ntrkr1)特異的キメラ抗原レセプター
|
ES2781175T3
(es)
|
2014-07-31 |
2020-08-31 |
Novartis Ag |
Subconjunto optimizado de células T que contienen un receptor de antígeno quimérico
|
WO2016016343A1
(en)
|
2014-07-31 |
2016-02-04 |
Cellectis |
Ror1 specific multi-chain chimeric antigen receptor
|
US10851149B2
(en)
|
2014-08-14 |
2020-12-01 |
The Trustees Of The University Of Pennsylvania |
Treatment of cancer using GFR α-4 chimeric antigen receptor
|
PL3183268T3
(pl)
|
2014-08-19 |
2020-09-07 |
Novartis Ag |
Chimeryczny receptor antygenowy (CAR) anty-CD123 do zastosowania w leczeniu nowotworu złośliwego
|
US11111288B2
(en)
|
2014-08-28 |
2021-09-07 |
Bioatla, Inc. |
Conditionally active chimeric antigen receptors for modified t-cells
|
EP3186284B1
(en)
|
2014-08-28 |
2022-04-06 |
BioAtla, Inc. |
Conditionally active chimeric antigen receptors for modified t-cells
|
EP3189132B1
(en)
*
|
2014-09-04 |
2020-06-24 |
Stemcell Technologies Inc. |
Soluble antibody complexes for t cell or nk cell activation and expansion
|
DK3189073T3
(da)
|
2014-09-04 |
2020-03-30 |
Cellectis |
Trophoblast-glycoprotein (5t4, tpbg)-specifikke kimære antigenreceptorer til cancerimmunterapi
|
US10987412B2
(en)
|
2014-09-17 |
2021-04-27 |
The John Hopkins University |
Reagents and methods for identifying, enriching, and/or expanding antigen-specific T cells
|
EA201790624A1
(ru)
|
2014-09-17 |
2017-08-31 |
Новартис Аг |
Нацеливание цитотоксических клеток с химерными рецепторами для адоптивной иммунотерапии
|
IL279420B1
(en)
|
2014-10-08 |
2024-05-01 |
Novartis Ag |
Biomarkers for predicting drug reactivity to chimeric antigen receptor therapy and their use
|
WO2016090034A2
(en)
|
2014-12-03 |
2016-06-09 |
Novartis Ag |
Methods for b cell preconditioning in car therapy
|
PT3628687T
(pt)
|
2014-12-12 |
2021-10-20 |
Bluebird Bio Inc |
Recetores do antigénio quimérico bcma
|
EP3757211A1
(en)
|
2014-12-19 |
2020-12-30 |
The Broad Institute, Inc. |
Methods for profiling the t-cell-receptor repertoire
|
US10975442B2
(en)
|
2014-12-19 |
2021-04-13 |
Massachusetts Institute Of Technology |
Molecular biomarkers for cancer immunotherapy
|
EP3240803B1
(en)
|
2014-12-29 |
2021-11-24 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
RU2017129455A
(ru)
|
2015-01-26 |
2019-03-04 |
Селлектис |
Сконструированные иммунные клетки с нокаутом рецептора т-клеток, снабженные химерными антигенными рецепторами, связывающимися с cd123, для лечения рецедивирующего/устойчивого острого миелоидного лейкоза или новообразования из бластных плазмоцитоидных дендритных клеток
|
WO2016123100A1
(en)
|
2015-01-26 |
2016-08-04 |
Fate Therapeutics, Inc. |
Methods and compositions for inducing hematopoietic cell differentiation
|
WO2016126608A1
(en)
|
2015-02-02 |
2016-08-11 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
KR20170137079A
(ko)
|
2015-03-11 |
2017-12-12 |
셀렉티스 |
그것들의 지속을 증가시키기 위한 동종이계 t 세포의 조작 및/또는 환자들 내로 이식 방법들
|
AU2016243124A1
(en)
|
2015-03-27 |
2017-11-02 |
University Of Southern California |
CAR T-cell therapy directed to LHR for the treatment of solid tumors
|
CN107106671B
(zh)
|
2015-04-03 |
2022-01-14 |
优瑞科生物技术公司 |
靶向afp肽/mhc复合体的构建体及其用途
|
US20180140602A1
(en)
|
2015-04-07 |
2018-05-24 |
Novartis Ag |
Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
|
SI3280729T1
(sl)
|
2015-04-08 |
2022-09-30 |
Novartis Ag |
Terapije CD20, terapije CD22 in kombinacija terapij s celico, ki izraža himerni antigenski receptor CD19 (CAR)
|
KR102208443B1
(ko)
|
2015-04-13 |
2021-01-27 |
화이자 인코포레이티드 |
B-세포 성숙 항원을 표적화하는 키메라 항원 수용체
|
US11896614B2
(en)
|
2015-04-17 |
2024-02-13 |
Novartis Ag |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
WO2016172583A1
(en)
|
2015-04-23 |
2016-10-27 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
JP2018513201A
(ja)
|
2015-04-25 |
2018-05-24 |
ザ ジェネラル ホスピタル コーポレイション |
抗fugetactic剤と抗癌剤の併用療法、および、癌の治療のための組成物
|
WO2016174652A1
(en)
|
2015-04-30 |
2016-11-03 |
Technion Research & Development Foundation Limited |
Chimeric antigen receptors and methods of their use
|
JP7340221B2
(ja)
|
2015-05-01 |
2023-09-07 |
ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、カリフォルニア |
グリカン依存性免疫療法分子
|
CN114107197A
(zh)
*
|
2015-05-13 |
2022-03-01 |
泰尔茂比司特公司 |
细胞扩增
|
JP2018515123A
(ja)
|
2015-05-18 |
2018-06-14 |
ティーシーアール2 セラピューティクス インク. |
融合タンパク質を用いたtcrの再プログラミングのための組成物及び方法
|
AR104718A1
(es)
|
2015-05-20 |
2017-08-09 |
Cellectis |
Receptores de antígenos quiméricos específicos de anti-gd3 para inmunoterapias contra el cáncer
|
CN116196401A
(zh)
|
2015-05-20 |
2023-06-02 |
博德研究所 |
共有的新抗原
|
BR112017024899A2
(pt)
|
2015-05-21 |
2018-11-13 |
Harpoon Therapeutics, Inc. |
proteínas de ligação trispecíficas e métodos de uso.
|
CA2987992A1
(en)
|
2015-06-04 |
2016-12-08 |
University Of Southern California |
Lym-1 and lym-2 targeted car cell immunotherapy
|
WO2016205749A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
CA2995036A1
(en)
|
2015-08-06 |
2017-02-09 |
Dana-Farber Cancer Institute, Inc. |
Tunable endogenous protein degradation
|
EP3331913A1
(en)
|
2015-08-07 |
2018-06-13 |
Novartis AG |
Treatment of cancer using chimeric cd3 receptor proteins
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
US10709775B2
(en)
|
2015-08-11 |
2020-07-14 |
Cellectis |
Cells for immunotherapy engineered for targeting CD38 antigen and for CD38 gene inactivation
|
ES2954480T3
(es)
|
2015-08-21 |
2023-11-22 |
Mayo Found Medical Education & Res |
Métodos y materiales para expandir linfocitos T específicos de antígeno en cultivo
|
AU2016315704B2
(en)
|
2015-08-31 |
2022-08-11 |
Helixmith Co., Ltd |
Anti-sialyl Tn chimeric antigen receptors
|
CN116334205A
(zh)
|
2015-09-03 |
2023-06-27 |
诺华股份有限公司 |
预测细胞因子释放综合征的生物标志物
|
WO2017049208A1
(en)
|
2015-09-18 |
2017-03-23 |
The General Hospital Corporation Dba Massachusetts General Hospital |
Localized delivery of anti-fugetactic agent for treatment of cancer
|
CA2999037A1
(en)
|
2015-09-23 |
2017-03-30 |
Cytoimmune Therapeutics, LLC |
Flt3 directed car cells for immunotherapy
|
US20190255107A1
(en)
|
2015-10-09 |
2019-08-22 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
SG10201913247XA
(en)
|
2015-10-23 |
2020-02-27 |
Eureka Therapeutics Inc |
Antibody/t-cell receptor chimeric constructs and uses thereof
|
WO2017075451A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
|
WO2017075478A2
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
|
WO2017075465A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
|
KR20180066263A
(ko)
|
2015-11-04 |
2018-06-18 |
페이트 세러퓨틱스, 인코포레이티드 |
조혈 세포 분화를 유도하기 위한 방법 및 조성물
|
KR20180066262A
(ko)
|
2015-11-04 |
2018-06-18 |
페이트 세러퓨틱스, 인코포레이티드 |
만능 세포의 유전자 조작
|
WO2017087708A1
(en)
|
2015-11-19 |
2017-05-26 |
The Brigham And Women's Hospital, Inc. |
Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
|
WO2017091786A1
(en)
|
2015-11-23 |
2017-06-01 |
Novartis Ag |
Optimized lentiviral transfer vectors and uses thereof
|
FI3383920T3
(fi)
|
2015-11-30 |
2024-04-10 |
Univ California |
Kasvainspesifinen hyötyaineen antaminen ja immuuniaktivointi käyttämällä erittäin spesifiseen kasvainsolun pinta-antigeeniin kohdentuvaa ihmisen vasta-ainetta
|
US11479755B2
(en)
|
2015-12-07 |
2022-10-25 |
2Seventy Bio, Inc. |
T cell compositions
|
US11052111B2
(en)
|
2015-12-08 |
2021-07-06 |
Chimera Bioengineering, Inc. |
Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses
|
WO2017112741A1
(en)
|
2015-12-22 |
2017-06-29 |
Novartis Ag |
Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
|
WO2017117112A1
(en)
|
2015-12-28 |
2017-07-06 |
Novartis Ag |
Methods of making chimeric antigen receptor -expressing cells
|
CA3009709A1
(en)
|
2015-12-30 |
2017-07-06 |
Novartis Ag |
Immune effector cell therapies with enhanced efficacy
|
GB201600328D0
(en)
|
2016-01-08 |
2016-02-24 |
Univ Oslo Hf |
Anti-CD37 chimeric antigen receptors and immune cells expressing them
|
UA125252C2
(uk)
|
2016-01-21 |
2022-02-09 |
Пфайзер Інк. |
Химерний антигенний рецептор, що націлений на варіант iii рецептора епідермального фактора росту
|
CA3016287A1
(en)
|
2016-03-04 |
2017-09-08 |
Novartis Ag |
Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
|
WO2017161051A1
(en)
*
|
2016-03-15 |
2017-09-21 |
Nexgenia, Inc. |
Cell-surface molecule binding stimuli-responsive polymer compositions and methods cross-reference to related applications
|
AU2017244108B2
(en)
|
2016-03-29 |
2021-03-18 |
University Of Southern California |
Chimeric antigen receptors targeting cancer
|
MY201207A
(en)
|
2016-04-01 |
2024-02-09 |
Amgen Inc |
Chimeric receptors to flt3 and methods of use thereof
|
EP3436036A4
(en)
|
2016-04-01 |
2020-03-18 |
Kite Pharma, Inc. |
BCMA-BINDING MOLECULES AND METHOD FOR USE THEREOF
|
PE20200400A1
(es)
|
2016-04-01 |
2020-02-26 |
Kite Pharma Inc |
Receptores quimericos y metodos de uso de los mismos
|
WO2017173256A1
(en)
|
2016-04-01 |
2017-10-05 |
Kite Pharma, Inc. |
Chimeric antigen and t cell receptors and methods of use
|
US11225638B2
(en)
|
2016-04-04 |
2022-01-18 |
CyteQuest, Inc. |
System, device and method for electroporation of cells
|
WO2017180993A1
(en)
|
2016-04-14 |
2017-10-19 |
Bluebird Bio, Inc. |
Salvage chimeric antigen receptor systems
|
KR20220133318A
(ko)
|
2016-04-15 |
2022-10-04 |
노파르티스 아게 |
선택적 단백질 발현을 위한 조성물 및 방법
|
WO2017181101A1
(en)
|
2016-04-15 |
2017-10-19 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods of chimeric alloantigen receptor t cells
|
EP3429633B1
(en)
|
2016-04-15 |
2021-02-24 |
Cellectis |
A method of engineering drug-specific hypersensitive t-cells for immunotherapy by gene inactivation
|
EP3429634A1
(en)
|
2016-04-15 |
2019-01-23 |
Cellectis |
A method of engineering prodrug-specific hypersensitive t-cells for immunotherapy by gene expression
|
EP3446119A1
(en)
|
2016-04-18 |
2019-02-27 |
The Broad Institute Inc. |
Improved hla epitope prediction
|
WO2017192776A1
(en)
*
|
2016-05-03 |
2017-11-09 |
The Trustees Of Columbia University In The City Of New York |
Method for improving expansion of t cells from patients
|
KR20230044567A
(ko)
|
2016-05-13 |
2023-04-04 |
바이오아트라, 인코퍼레이티드 |
항 ror2 항체, 항체 단편 및 이의 면역접합체와 이것들의 용도
|
CN109641047A
(zh)
|
2016-05-20 |
2019-04-16 |
哈普恩治疗公司 |
单结构域血清白蛋白结合蛋白质
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
WO2017210617A2
(en)
|
2016-06-02 |
2017-12-07 |
Porter, David, L. |
Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
|
WO2017211900A1
(en)
|
2016-06-07 |
2017-12-14 |
Max-Delbrück-Centrum für Molekulare Medizin |
Chimeric antigen receptor and car-t cells that bind bcma
|
US11787848B2
(en)
|
2016-06-08 |
2023-10-17 |
Precigen, Inc. |
CD33 specific chimeric antigen receptors
|
JP7195154B2
(ja)
|
2016-07-06 |
2022-12-23 |
セレクティス |
初代免疫細胞における逐次遺伝子編集
|
JP2018035137A
(ja)
|
2016-07-13 |
2018-03-08 |
マブイミューン ダイアグノスティックス エイジーMabimmune Diagnostics Ag |
新規な抗線維芽細胞活性化タンパク質(fap)結合薬剤およびその使用
|
WO2018013918A2
(en)
|
2016-07-15 |
2018-01-18 |
Novartis Ag |
Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
|
CA3031289A1
(en)
|
2016-07-18 |
2018-01-25 |
Helix Biopharma Corp. |
Car immune cells to treat cancer
|
JP7038100B2
(ja)
*
|
2016-07-21 |
2022-03-17 |
バークレー ライツ,インコーポレイテッド |
マイクロ流体デバイスでのtリンパ球の選別
|
EP3491117A4
(en)
*
|
2016-07-26 |
2020-07-29 |
Biomagnetic Solutions LLC |
SIMULTANEOUS SEPARATION AND ACTIVATION OF T CELLS FROM BLOOD PRODUCTS WITH FOLLOWING STIMULATION FOR THE EXPANSION OF T CELLS
|
AU2017302668B9
(en)
|
2016-07-28 |
2023-06-22 |
Novartis Ag |
Combination therapies of chimeric antigen receptors and PD-1 inhibitors
|
CA3032581A1
(en)
|
2016-08-01 |
2018-02-08 |
Novartis Ag |
Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
|
EP3494138A1
(en)
|
2016-08-02 |
2019-06-12 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
US11630103B2
(en)
|
2016-08-17 |
2023-04-18 |
The Broad Institute, Inc. |
Product and methods useful for modulating and evaluating immune responses
|
US10294454B2
(en)
|
2016-08-24 |
2019-05-21 |
General Electric Company |
Methods and kits for cell activation
|
CA3033911A1
(en)
*
|
2016-08-26 |
2018-03-01 |
Juno Therapeutics, Inc. |
Methods of enumerating particles present in a cell composition
|
WO2018045177A1
(en)
|
2016-09-01 |
2018-03-08 |
Chimera Bioengineering, Inc. |
Gold optimized car t-cells
|
US20190262399A1
(en)
|
2016-09-07 |
2019-08-29 |
The Broad Institute, Inc. |
Compositions and methods for evaluating and modulating immune responses
|
EP3510398A1
(en)
*
|
2016-09-12 |
2019-07-17 |
Isoplexis Corporation |
System and methods for multiplexed analysis of cellular and other immunotherapeutics
|
CA3036972A1
(en)
|
2016-09-14 |
2018-03-22 |
Janssen Biotech, Inc. |
Chimeric antigen receptors comprising bcma-specific fibronectin type iii domains and uses thereof
|
JP6908710B2
(ja)
|
2016-09-21 |
2021-07-28 |
ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
ケモカイン受容体ccr4を標的にするキメラ抗原受容体(car)およびその使用
|
PL3445787T3
(pl)
|
2016-10-07 |
2021-05-31 |
TCR2 Therapeutics Inc. |
Kompozycje i sposoby reprogramowania receptorów limfocytów t przy użyciu białek fuzyjnych
|
AR110676A1
(es)
|
2016-10-07 |
2019-04-24 |
Novartis Ag |
Tratamiento del cáncer utilizando receptores de antígenos quiméricos
|
WO2018067991A1
(en)
|
2016-10-07 |
2018-04-12 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
WO2018073391A1
(en)
|
2016-10-19 |
2018-04-26 |
Cellectis |
Targeted gene insertion for improved immune cells therapy
|
WO2018073394A1
(en)
|
2016-10-19 |
2018-04-26 |
Cellectis |
Cell death inducing chimeric antigen receptors
|
EP3528823A4
(en)
*
|
2016-10-24 |
2020-04-15 |
GPB Scientific, LLC |
DETERMINIST LATERAL SHIFTING IN THE PRODUCTION OF CELLS AND COMPOSITIONS FOR THERAPEUTIC USE
|
US11332713B2
(en)
|
2016-11-16 |
2022-05-17 |
KSQ Therapeutics, Inc. |
Gene-regulating compositions and methods for improved immunotherapy
|
JP7263235B2
(ja)
|
2016-11-17 |
2023-04-24 |
2セブンティ バイオ インコーポレイテッド |
TGFβシグナルコンバーター
|
US11851491B2
(en)
|
2016-11-22 |
2023-12-26 |
TCR2 Therapeutics Inc. |
Compositions and methods for TCR reprogramming using fusion proteins
|
JP6812551B2
(ja)
|
2016-11-23 |
2021-01-13 |
ハープーン セラピューティクス,インク. |
前立腺特異的膜抗原結合タンパク質
|
US10844134B2
(en)
|
2016-11-23 |
2020-11-24 |
Harpoon Therapeutics, Inc. |
PSMA targeting trispecific proteins and methods of use
|
WO2018111340A1
(en)
|
2016-12-16 |
2018-06-21 |
Novartis Ag |
Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
|
JP2020513754A
(ja)
|
2016-12-21 |
2020-05-21 |
ティーシーアール2 セラピューティクス インク. |
がん治療用に操作されたt細胞
|
WO2018115189A1
(en)
|
2016-12-21 |
2018-06-28 |
Cellectis |
Stably enginereed proteasome inhibitor resistant immune cells for immunotherapy
|
WO2018127585A1
(en)
|
2017-01-06 |
2018-07-12 |
Txcell |
Monospecific regulatory t cell population with cytotoxicity for b cells
|
EP3346001A1
(en)
|
2017-01-06 |
2018-07-11 |
TXCell |
Monospecific regulatory t cell population with cytotoxicity for b cells
|
EP3568474A1
(en)
|
2017-01-10 |
2019-11-20 |
Intrexon Corporation |
Modulating expression of polypeptides via new gene switch expression systems
|
EP3568468A4
(en)
|
2017-01-12 |
2020-12-30 |
Eureka Therapeutics, Inc. |
RECOMBINATION PRODUCTS TARGETING PEPTIDE HISTONE H3 / MHC COMPLEXES AND THEIR USES
|
GB201700553D0
(en)
|
2017-01-12 |
2017-03-01 |
Genagon Therapeutics Ab |
Therapeutic agents
|
EP3574116A1
(en)
|
2017-01-24 |
2019-12-04 |
The Broad Institute, Inc. |
Compositions and methods for detecting a mutant variant of a polynucleotide
|
WO2018140725A1
(en)
|
2017-01-26 |
2018-08-02 |
Novartis Ag |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
JP7182162B2
(ja)
|
2017-01-27 |
2022-12-02 |
株式会社ステムリム |
心筋症、陳旧性心筋梗塞および慢性心不全の治療薬
|
EP3577134A1
(en)
|
2017-01-31 |
2019-12-11 |
Novartis AG |
Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
|
WO2018148180A2
(en)
|
2017-02-07 |
2018-08-16 |
Immune Design Corp. |
Materials and methods for identifying and treating cancer patients
|
AU2018219289A1
(en)
|
2017-02-08 |
2019-09-05 |
Dana-Farber Cancer Institute, Inc. |
Regulating chimeric antigen receptors
|
ES2900233T3
(es)
|
2017-02-14 |
2022-03-16 |
Kite Pharma Inc |
Moléculas que se unen a CD70 y métodos de uso de las mismas
|
WO2018160754A2
(en)
|
2017-02-28 |
2018-09-07 |
Harpoon Therapeutics, Inc. |
Inducible monovalent antigen binding protein
|
WO2018169922A2
(en)
|
2017-03-13 |
2018-09-20 |
Kite Pharma, Inc. |
Chimeric antigen receptors for melanoma and uses thereof
|
AU2018235130B2
(en)
|
2017-03-15 |
2023-12-07 |
Oxford Biomedica (Uk) Limited |
Method
|
WO2018175676A1
(en)
|
2017-03-23 |
2018-09-27 |
The General Hospital Corporation |
Cxcr4/cxcr7 blockade and treatment of human papilloma virus-associated disease
|
EP3592379B1
(en)
|
2017-03-31 |
2024-04-24 |
Cellectis SA |
Universal anti-cd22 chimeric antigen receptor engineered immune cells
|
WO2018183908A1
(en)
|
2017-03-31 |
2018-10-04 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating ovarian tumors
|
WO2018183921A1
(en)
|
2017-04-01 |
2018-10-04 |
The Broad Institute, Inc. |
Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
|
AU2018250148B2
(en)
|
2017-04-03 |
2021-09-23 |
Kite Pharma, Inc. |
Treatment using chimeric receptor T cells incorporating optimized polyfunctional T cells
|
EP3610266A4
(en)
|
2017-04-12 |
2021-04-21 |
Massachusetts Eye and Ear Infirmary |
TUMOR SIGNATURE OF METASTASIS, COMPOSITIONS OF SUBSTANCES AND USES THEREOF
|
WO2018189360A1
(en)
|
2017-04-13 |
2018-10-18 |
Cellectis |
New sequence specific reagents targeting ccr5 in primary hematopoietic cells
|
BR112019021857A2
(pt)
|
2017-04-19 |
2020-06-02 |
Allogene Therapeutics, Inc. |
Métodos e composições de célula t aperfeiçoada
|
JOP20180042A1
(ar)
|
2017-04-24 |
2019-01-30 |
Kite Pharma Inc |
نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام
|
KR20200014294A
(ko)
|
2017-04-26 |
2020-02-10 |
유레카 쎄라퓨틱스, 인코포레이티드 |
키메라 항체/t-세포 수용체 구축물 및 그의 용도
|
WO2018200586A1
(en)
|
2017-04-26 |
2018-11-01 |
Eureka Therapeutics, Inc. |
Constructs specifically recognizing glypican 3 and uses thereof
|
EP3615055A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
CA3063362A1
(en)
|
2017-05-12 |
2018-11-15 |
Harpoon Therapeutics, Inc. |
Msln targeting trispecific proteins and methods of use
|
CN113896792A
(zh)
|
2017-05-12 |
2022-01-07 |
哈普恩治疗公司 |
间皮素结合蛋白质
|
WO2018206791A1
(en)
|
2017-05-12 |
2018-11-15 |
Cellectis |
Protease based switch chimeric antigen receptors for safer cell immunotherapy
|
CA3063807A1
(en)
|
2017-05-18 |
2018-11-22 |
Umc Utrecht Holding B.V. |
Compositions and methods for cell targeting therapies
|
EP3630950A1
(en)
|
2017-05-26 |
2020-04-08 |
Kite Pharma, Inc. |
Methods of making and using embryonic mesenchymal progenitor cells
|
US20230181634A1
(en)
|
2017-06-02 |
2023-06-15 |
Pfizer Inc. |
Chimeric antigen receptors targeting flt3
|
KR20230115343A
(ko)
|
2017-06-07 |
2023-08-02 |
프레시전 인코포레이티드 |
신규의 세포 태그의 발현
|
EP3638295A1
(en)
|
2017-06-13 |
2020-04-22 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
US11897953B2
(en)
|
2017-06-14 |
2024-02-13 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
CN110785187B
(zh)
|
2017-06-22 |
2024-04-05 |
诺华股份有限公司 |
针对cd73的抗体分子及其用途
|
EP3642240A1
(en)
|
2017-06-22 |
2020-04-29 |
Novartis AG |
Antibody molecules to cd73 and uses thereof
|
WO2019005897A1
(en)
|
2017-06-28 |
2019-01-03 |
Regeneron Pharmaceuticals, Inc. |
HUMAN ANTI-PAPILLOMAVIRUS ANTIGEN BINDING PROTEINS AND METHODS OF USE THEREOF
|
US20220233588A1
(en)
|
2017-06-30 |
2022-07-28 |
Cellectis |
Cellular immunotherapy for repetitive administration
|
US12049643B2
(en)
|
2017-07-14 |
2024-07-30 |
The Broad Institute, Inc. |
Methods and compositions for modulating cytotoxic lymphocyte activity
|
WO2019018402A2
(en)
|
2017-07-17 |
2019-01-24 |
Janssen Biotech, Inc. |
ANTIGEN-BINDING REGIONS DIRECTED AGAINST FIBRONECTIN TYPE III DOMAINS AND METHODS OF USING THE SAME
|
WO2019016360A1
(en)
|
2017-07-21 |
2019-01-24 |
Cellectis |
MODIFIED IMMUNE CELLS RESISTANT TO TUMOR MICRO-ENVIRONMENT
|
CN111107871A
(zh)
*
|
2017-07-21 |
2020-05-05 |
伯克利之光生命科技公司 |
抗原呈递合成表面、共价官能化表面、活化t细胞及其用途
|
CN111094349A
(zh)
|
2017-08-23 |
2020-05-01 |
马克思-德布鲁克-分子医学中心亥姆霍兹联合会 |
嵌合抗原受体和结合cxcr5的car-t细胞
|
WO2019040994A1
(en)
|
2017-09-01 |
2019-03-07 |
The Australian National University |
IMMUNOREGULATOR MOLECULES AND USES THEREOF
|
CA3076261A1
(en)
|
2017-09-19 |
2019-03-28 |
The University Of British Columbia |
Anti-hla-a2 antibodies and methods of using the same
|
JP7317023B2
(ja)
|
2017-09-20 |
2023-07-28 |
ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア |
新規抗hla-a2抗体、およびその使用
|
US11618896B2
(en)
|
2017-09-21 |
2023-04-04 |
The Broad Institute, Inc. |
Systems, methods, and compositions for targeted nucleic acid editing
|
US12043870B2
(en)
|
2017-10-02 |
2024-07-23 |
The Broad Institute, Inc. |
Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
|
AU2018346719A1
(en)
|
2017-10-06 |
2020-04-23 |
Oslo Universitetssykehus Hf |
Chimeric antigen receptors
|
WO2019072824A1
(en)
|
2017-10-09 |
2019-04-18 |
Cellectis |
IMPROVED ANTI-CD123 CAR IN UNIVERSAL MODIFIED IMMUNE T LYMPHOCYTES
|
CR20200196A
(es)
|
2017-10-13 |
2020-06-05 |
Harpoon Therapeutics Inc |
Proteínas trispecìficas y mètodos de uso
|
EA202090739A1
(ru)
|
2017-10-13 |
2020-09-07 |
Харпун Терапьютикс, Инк. |
Белки, связывающие антиген созревания в-клеток
|
CA3084470A1
(en)
|
2017-10-18 |
2019-04-25 |
Kite Pharma, Inc. |
Methods of administering chimeric antigen receptor immunotherapy
|
KR20200075851A
(ko)
|
2017-10-19 |
2020-06-26 |
셀렉티스 |
개선된 면역 세포들 치료를 위한 nk 억제제들의 타겟인 유전자 통합
|
SG11202003177RA
(en)
|
2017-10-25 |
2020-05-28 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
US20210179709A1
(en)
|
2017-10-31 |
2021-06-17 |
Novartis Ag |
Anti-car compositions and methods
|
WO2019089844A1
(en)
|
2017-11-01 |
2019-05-09 |
Allogene Therapeutics, Inc. |
Modified caspase-9 polypeptides and methods of use thereof
|
JP7357613B2
(ja)
|
2017-11-06 |
2023-10-06 |
ラディック インスティテュート フォア キャンサー リサーチ リミテッド |
リンパ球の拡大方法
|
US12018080B2
(en)
|
2017-11-13 |
2024-06-25 |
The Broad Institute, Inc. |
Methods and compositions for treating cancer by targeting the CLEC2D-KLRB1 pathway
|
TW201922774A
(zh)
|
2017-11-15 |
2019-06-16 |
瑞士商諾華公司 |
標靶bcma嵌合抗原受體、標靶cd19嵌合抗原受體及組合療法
|
US11390655B2
(en)
|
2017-11-16 |
2022-07-19 |
Kite Pharma, Inc. |
Modified chimeric antigen receptors and methods of use
|
TW201925782A
(zh)
|
2017-11-30 |
2019-07-01 |
瑞士商諾華公司 |
靶向bcma之嵌合抗原受體及其用途
|
EP3718561A4
(en)
|
2017-12-01 |
2021-07-21 |
Stemrim Inc. |
Therapy for inflammatory bowel disease
|
US20200384104A1
(en)
*
|
2017-12-15 |
2020-12-10 |
Northwestern University |
Structure-Function Relationships in the Development of Immunotherapeutic Agents
|
US11365390B2
(en)
|
2017-12-19 |
2022-06-21 |
Xcell Biosciences, Inc. |
Methods of modulating cell phenotype by way of regulating the gaseous environment
|
US11859176B2
(en)
|
2017-12-22 |
2024-01-02 |
Industrial Technology Research Institute |
Method for in vitro activation and/or expansion of immune cells
|
US11994512B2
(en)
|
2018-01-04 |
2024-05-28 |
Massachusetts Institute Of Technology |
Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
|
CN112218651A
(zh)
|
2018-01-08 |
2021-01-12 |
诺华公司 |
用于与嵌合抗原受体疗法组合的免疫增强rna
|
PL3737765T3
(pl)
|
2018-01-12 |
2022-04-11 |
Curocell Inc. |
Komórki układu odpornościowego wzmocnione z użyciem podwójnego shrna i kompozycja zawierająca te komórki
|
CA3087481A1
(en)
|
2018-01-15 |
2019-07-18 |
Pfizer Inc. |
Methods of administering chimeric antigen receptor immunotherapy in combination with 4-1bb agonist
|
CN112236172A
(zh)
|
2018-01-30 |
2021-01-15 |
福宏治疗公司 |
用于治疗病症的方法和化合物
|
EP3694546A1
(en)
|
2018-01-30 |
2020-08-19 |
Cellectis |
Combination comprising allogeneic immune cells deficient for an antigen present on both t-cells and pathological cells and therapeutic antibody against said antigen
|
CA3090249A1
(en)
|
2018-01-31 |
2019-08-08 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
PE20210708A1
(es)
|
2018-02-01 |
2021-04-16 |
Pfizer |
Anticuerpos especificos para cd70 y sus usos
|
WO2019152742A1
(en)
|
2018-02-01 |
2019-08-08 |
Pfizer Inc. |
Chimeric antigen receptors targeting cd70
|
EP3752203A1
(en)
|
2018-02-13 |
2020-12-23 |
Novartis AG |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
AU2019222550B2
(en)
|
2018-02-16 |
2022-10-27 |
Kite Pharma, Inc. |
Modified pluripotent stem cells and methods of making and use
|
GB201803178D0
(en)
|
2018-02-27 |
2018-04-11 |
Univ Oslo Hf |
Specific binding molecules for htert
|
US20200393355A1
(en)
|
2018-02-28 |
2020-12-17 |
Juno Therapeutics, Inc. |
Methods for detecting particles present in a cell composition
|
WO2019169290A1
(en)
|
2018-03-02 |
2019-09-06 |
Allogene Therapeutics, Inc. |
Inducible chimeric cytokine receptors
|
KR20230020023A
(ko)
|
2018-03-14 |
2023-02-09 |
서피스 온콜로지, 인크. |
Cd39에 결합하는 항체 및 이의 용도
|
KR20200133219A
(ko)
|
2018-03-15 |
2020-11-26 |
케이에스큐 세러퓨틱스 인코포레이티드 |
개선된 면역요법을 위한 유전자-조절 조성물 및 방법
|
BR112020018658A2
(pt)
|
2018-03-15 |
2020-12-29 |
KSQ Therapeutics, Inc. |
Composições de regulação gênica e métodos para imu-noterapia aprimorada
|
DE102018108612A1
(de)
|
2018-03-21 |
2019-09-26 |
Immatics US, Inc. |
Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
|
SG11202005200XA
(en)
|
2018-03-22 |
2020-07-29 |
Windmil Therapeutics Inc |
Prostate cancer specific marrow infiltrating lymphocytes and uses thereof
|
JP7479290B2
(ja)
|
2018-04-10 |
2024-05-08 |
アムジエン・インコーポレーテツド |
Dll3に対するキメラ受容体及びその使用方法
|
EP3774872A1
(en)
|
2018-04-12 |
2021-02-17 |
Kite Pharma, Inc. |
Chimeric receptor t cell treatment using characteristics of the tumor microenvironment
|
KR20210005879A
(ko)
|
2018-04-13 |
2021-01-15 |
상가모 테라퓨틱스 프랑스 |
인터류킨-23 수용체에 특이적인 키메라 항원 수용체
|
US12054529B2
(en)
|
2018-04-20 |
2024-08-06 |
Medizinische Hochschule Hannover |
Chimeric antigen receptor and CAR-T cells that bind a herpes virus antigen
|
US11957695B2
(en)
|
2018-04-26 |
2024-04-16 |
The Broad Institute, Inc. |
Methods and compositions targeting glucocorticoid signaling for modulating immune responses
|
US20210047405A1
(en)
|
2018-04-27 |
2021-02-18 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
EP3788369A1
(en)
|
2018-05-01 |
2021-03-10 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
WO2019217661A1
(en)
*
|
2018-05-09 |
2019-11-14 |
Yale University |
Compositions and systems for ex vivo cell modulation and methods of use thereof
|
US20190345261A1
(en)
|
2018-05-10 |
2019-11-14 |
Sensei Biotherapeutics, Inc. |
Aspartate beta-hydroxylase chimeric antigen receptors and uses thereof
|
CA3099364A1
(en)
|
2018-05-11 |
2019-11-14 |
Crispr Therapeutics Ag |
Methods and compositions for treating cancer comprising engineered t cells comprising modified chimeric antigen receptors
|
WO2019219979A1
(en)
|
2018-05-18 |
2019-11-21 |
Umc Utrecht Holding B.V. |
Compositions and methods for cell targeting therapies
|
US20210213063A1
(en)
|
2018-05-25 |
2021-07-15 |
Novartis Ag |
Combination therapy with chimeric antigen receptor (car) therapies
|
AR126019A1
(es)
|
2018-05-30 |
2023-09-06 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
WO2019232244A2
(en)
|
2018-05-31 |
2019-12-05 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
US20210371932A1
(en)
|
2018-06-01 |
2021-12-02 |
Massachusetts Institute Of Technology |
Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
|
KR20210018833A
(ko)
|
2018-06-05 |
2021-02-18 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
근육 특이적 키나제 키메라 자가항체 수용체 세포의 조성물 및 방법
|
TW202016139A
(zh)
|
2018-06-13 |
2020-05-01 |
瑞士商諾華公司 |
Bcma 嵌合抗原受體及其用途
|
US12036240B2
(en)
|
2018-06-14 |
2024-07-16 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
CN112368021A
(zh)
|
2018-06-14 |
2021-02-12 |
蓝鸟生物公司 |
Cd79a嵌合抗原受体
|
WO2019241549A1
(en)
|
2018-06-15 |
2019-12-19 |
A2 Biotherapeutics, Inc. |
Foxp3-expressing car-t regulatory cells
|
EP3806904A4
(en)
|
2018-06-18 |
2022-04-27 |
Eureka Therapeutics, Inc. |
PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) TARGETED CONSTRUCTS AND USES THEREOF
|
WO2019245817A1
(en)
|
2018-06-19 |
2019-12-26 |
Armo Biosciences, Inc. |
Compositions and methods of use of il-10 agents in conjunction with chimeric antigen receptor cell therapy
|
WO2019243888A1
(en)
|
2018-06-22 |
2019-12-26 |
Kite Pharma Eu B.V. |
Compositions and methods for making engineered t cells
|
US20210268028A1
(en)
|
2018-07-02 |
2021-09-02 |
Cellectis |
Chimeric antigen receptors (car)-expressing cells and combination treatment for immunotherapy of patients with relapse refractory adverse genetic risk aml
|
US20210330788A1
(en)
|
2018-07-11 |
2021-10-28 |
Celgene Corporation |
Uses of anti-bcma chimeric antigen receptors
|
MA53167A
(fr)
|
2018-07-18 |
2021-05-26 |
Amgen Inc |
Récepteurs chimériques de steap1 et procédés d'utilisation associées
|
MD3823665T2
(ro)
|
2018-07-19 |
2024-05-31 |
Regeneron Pharma |
Receptori antigenci chimerici cu specificitate BCMA și utilizările acestora
|
KR20240103033A
(ko)
|
2018-08-02 |
2024-07-03 |
카이트 파마 인코포레이티드 |
키메라 항원 수용체 요법 t 세포 확장 동역학 및 그의 용도
|
BR112021002579A2
(pt)
|
2018-08-10 |
2021-05-11 |
Sangamo Therapeutics France |
novas construções de car compreendendo os domínios de tnfr2
|
IL294471B2
(en)
|
2018-08-13 |
2024-07-01 |
Rootpath Genomics Inc |
High-throughput cloning of bifirate immunoreceptor conjugated polynucleotides and their applications
|
US20210355522A1
(en)
|
2018-08-20 |
2021-11-18 |
The Broad Institute, Inc. |
Inhibitors of rna-guided nuclease activity and uses thereof
|
WO2020041387A1
(en)
|
2018-08-20 |
2020-02-27 |
The Brigham And Women's Hospital, Inc. |
Degradation domain modifications for spatio-temporal control of rna-guided nucleases
|
US20210177832A1
(en)
|
2018-08-20 |
2021-06-17 |
The Broad Institute, Inc. |
Inhibitors of rna-guided nuclease target binding and uses thereof
|
KR20210069048A
(ko)
|
2018-08-30 |
2021-06-10 |
티씨알2 테라퓨틱스 인크. |
융합 단백질을 이용하는 tcr 재프로그래밍을 위한 조성물 및 방법
|
US20210340279A1
(en)
|
2018-08-31 |
2021-11-04 |
Yale University |
Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators
|
WO2020047449A2
(en)
|
2018-08-31 |
2020-03-05 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
CN112912105B
(zh)
|
2018-08-31 |
2024-07-16 |
因维克蒂斯股份有限公司 |
针对多种hla-g同种型的嵌合抗原受体
|
SG11202101825QA
(en)
|
2018-08-31 |
2021-03-30 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
SG11202102489XA
(en)
|
2018-09-21 |
2021-04-29 |
Berkeley Lights Inc |
Functionalized well plate, methods of preparation and use thereof
|
KR20210086623A
(ko)
|
2018-09-25 |
2021-07-08 |
하푼 테라퓨틱스, 인크. |
Ddl3 결합 단백질 및 사용 방법
|
WO2020069409A1
(en)
|
2018-09-28 |
2020-04-02 |
Novartis Ag |
Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
|
EP3856779A1
(en)
|
2018-09-28 |
2021-08-04 |
Novartis AG |
Cd22 chimeric antigen receptor (car) therapies
|
US20210382068A1
(en)
|
2018-10-02 |
2021-12-09 |
Dana-Farber Cancer Institute, Inc. |
Hla single allele lines
|
WO2020081730A2
(en)
|
2018-10-16 |
2020-04-23 |
Massachusetts Institute Of Technology |
Methods and compositions for modulating microenvironment
|
EA202191107A1
(ru)
|
2018-10-23 |
2021-09-17 |
Ридженерон Фармасьютикалз, Инк. |
T-клеточные рецепторы ny-eso-1 и способы их применения
|
WO2020095249A1
(en)
|
2018-11-07 |
2020-05-14 |
Crispr Therapeutics Ag |
Anti-liv1 immune cell cancer therapy
|
JP2022512882A
(ja)
|
2018-11-07 |
2022-02-07 |
クリスパー セラピューティクス アクチェンゲゼルシャフト |
抗cd33免疫細胞癌療法
|
US20210290678A1
(en)
|
2018-11-07 |
2021-09-23 |
Crispr Therapeutics Ag |
Anti-ptk7 immune cell cancer therapy
|
EP3876979A4
(en)
|
2018-11-08 |
2022-08-24 |
NexImmune, Inc. |
COMPOSITIONS OF T LYMPHOCYTES WITH ENHANCED PHENOTYPIC PROPERTIES
|
US20220009993A1
(en)
|
2018-11-14 |
2022-01-13 |
Fundación Pública Andaluza Progreso Y Salud |
Polynucleotide for safer and more effective immunotherapies
|
US20200268797A1
(en)
|
2018-11-30 |
2020-08-27 |
Janssen Biotech, Inc. |
Gamma delta t cells and uses thereof
|
CA3121268A1
(en)
|
2018-12-10 |
2020-06-18 |
Amgen Inc. |
Mutated piggybac transposase
|
CA3177829A1
(en)
|
2018-12-12 |
2020-06-18 |
Kite Pharma, Inc. |
Chimeric antigen and t cell receptors and methods of use
|
WO2020131586A2
(en)
|
2018-12-17 |
2020-06-25 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
US11739156B2
(en)
|
2019-01-06 |
2023-08-29 |
The Broad Institute, Inc. Massachusetts Institute of Technology |
Methods and compositions for overcoming immunosuppression
|
GB201900858D0
(en)
|
2019-01-22 |
2019-03-13 |
Price Nicola Kaye |
Receptors providing targeted costimulation for adoptive cell therapy
|
US20230066136A1
(en)
|
2019-01-29 |
2023-03-02 |
Foghorn Therapeutics Inc. |
Compounds and uses thereof
|
BR112021016046A2
(pt)
|
2019-02-15 |
2021-11-09 |
Editas Medicine Inc |
Células assassinas naturais modificadas (nk) para imunoterapia
|
WO2020172553A1
(en)
|
2019-02-22 |
2020-08-27 |
Novartis Ag |
Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
|
AU2020232242A1
(en)
|
2019-03-01 |
2021-09-09 |
Revolution Medicines, Inc. |
Bicyclic heteroaryl compounds and uses thereof
|
MX2021010323A
(es)
|
2019-03-01 |
2021-12-10 |
Revolution Medicines Inc |
Compuestos bicíclicos de heterociclilo y usos de este.
|
PE20220495A1
(es)
|
2019-03-01 |
2022-04-07 |
Allogene Therapeutics Inc |
Receptores antigenicos quimericos y agentes de union dirigidos a dll3
|
EP3935151A1
(en)
|
2019-03-08 |
2022-01-12 |
Klinikum der Universität München |
Ccr8 expressing lymphocytes for targeted tumor therapy
|
US20220154282A1
(en)
|
2019-03-12 |
2022-05-19 |
The Broad Institute, Inc. |
Detection means, compositions and methods for modulating synovial sarcoma cells
|
KR20230146132A
(ko)
|
2019-03-15 |
2023-10-18 |
카티전 테라퓨틱스, 인코포레이티드 |
항-bcma 키메라 항원 수용체
|
EP3942023A1
(en)
|
2019-03-18 |
2022-01-26 |
The Broad Institute, Inc. |
Compositions and methods for modulating metabolic regulators of t cell pathogenicity
|
EP3946435B1
(en)
|
2019-03-25 |
2023-12-27 |
Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft |
Enhancement of cytolytic t-cell activity by inhibiting ebag9
|
US11090336B2
(en)
|
2019-03-27 |
2021-08-17 |
The Trustees Of The University Of Pennsylvania |
Tn-MUC1 chimeric antigen receptor (CAR) T cell therapy
|
US20220195060A1
(en)
|
2019-04-05 |
2022-06-23 |
2Seventy Bio, Inc. |
Manufacturing anti-bcma car t cells
|
WO2020206238A2
(en)
|
2019-04-05 |
2020-10-08 |
Rootpath Genomics, Inc. |
Compositions and methods for t-cell receptor gene assembly
|
US20220143094A1
(en)
|
2019-04-19 |
2022-05-12 |
Chugai Seiyaku Kabushiki Kaisha |
Chimeric receptor that recognizes engineered site in antibody
|
WO2020219742A1
(en)
|
2019-04-24 |
2020-10-29 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
EP3959235B1
(en)
|
2019-04-26 |
2023-07-26 |
Allogene Therapeutics, Inc. |
Rituximab-resistant chimeric antigen receptors and uses thereof
|
CA3132509A1
(en)
|
2019-04-26 |
2020-10-29 |
Allogene Therapeutics, Inc. |
Methods of manufacturing allogeneic car t cells
|
MX2021013394A
(es)
|
2019-05-03 |
2022-01-04 |
Kite Pharma Inc |
Métodos para administrar inmunoterapia con receptor de antígeno quimérico.
|
EP3965830A1
(en)
|
2019-05-07 |
2022-03-16 |
ModernaTX, Inc. |
Differentially expressed immune cell micrornas for regulation of protein expression
|
SG11202112637TA
(en)
|
2019-05-14 |
2021-12-30 |
Harpoon Therapeutics Inc |
EpCAM BINDING PROTEINS AND METHODS OF USE
|
US20200399578A1
(en)
*
|
2019-05-16 |
2020-12-24 |
CyteQuest, Inc. |
Devices, Methods, and Systems for Electroporation
|
WO2020236967A1
(en)
|
2019-05-20 |
2020-11-26 |
The Broad Institute, Inc. |
Random crispr-cas deletion mutant
|
WO2020243371A1
(en)
|
2019-05-28 |
2020-12-03 |
Massachusetts Institute Of Technology |
Methods and compositions for modulating immune responses
|
CA3141509A1
(en)
|
2019-06-05 |
2020-12-10 |
Deutsches Zentrum Fur Neurodegenerative Erkrankungen E.V. (Dzne) |
Chimeric autoantibody receptor (caar) that binds autoantibodies targeting the central nervous system in neurological autoimmune disease
|
JP2022538836A
(ja)
|
2019-06-27 |
2022-09-06 |
クリスパー セラピューティクス アクチェンゲゼルシャフト |
がんを治療するためのキメラ抗原受容体t細胞及びnk細胞阻害剤の使用
|
US20220267452A1
(en)
|
2019-07-12 |
2022-08-25 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-mutation type fgfr3 antibody and use therefor
|
BR112022001194A2
(pt)
|
2019-07-24 |
2022-06-07 |
Regeneron Pharma |
Receptores de antígeno quimérico com especificidade de mage a4 e usos dos mesmos
|
CN110387058A
(zh)
*
|
2019-07-24 |
2019-10-29 |
南通大学 |
一种促进细胞在水凝胶上面正常生长的方法
|
WO2021030182A1
(en)
|
2019-08-09 |
2021-02-18 |
A2 Biotherapeutics, Inc. |
Bifunctional single variable domain t cell receptors and uses thereof
|
US20220282333A1
(en)
|
2019-08-13 |
2022-09-08 |
The General Hospital Corporation |
Methods for predicting outcomes of checkpoint inhibition and treatment thereof
|
WO2021035170A1
(en)
|
2019-08-21 |
2021-02-25 |
Precision Biosciences, Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
AU2020337428A1
(en)
|
2019-08-27 |
2022-03-17 |
Janssen Biotech, Inc. |
Chimeric antigen receptor system and uses thereof
|
US20220298501A1
(en)
|
2019-08-30 |
2022-09-22 |
The Broad Institute, Inc. |
Crispr-associated mu transposase systems
|
CA3150151A1
(en)
|
2019-09-06 |
2021-03-11 |
Jonathan Alexander Terrett |
GENETICALLY MODIFIED T LYMPHOCYTES WITH IMPROVED PERSISTENCE IN CULTURE
|
AU2020347276A1
(en)
|
2019-09-12 |
2022-03-17 |
Massachusetts Institute Of Technology |
Engineered adeno-associated virus capsids
|
CA3145940A1
(en)
|
2019-09-16 |
2021-03-25 |
Scott Chappel |
Anti-cd39 antibody compositions and methods
|
WO2021053559A1
(en)
|
2019-09-18 |
2021-03-25 |
Novartis Ag |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
CA3155930A1
(en)
|
2019-09-27 |
2021-04-01 |
Starkage Therapeutics |
SENESCENT CELL-ASSOCIATED ANTIGEN-BINDING DOMAINS, ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS COMPRISING THEM, AND USES THEREOF
|
US11981922B2
(en)
|
2019-10-03 |
2024-05-14 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
|
US11793787B2
(en)
|
2019-10-07 |
2023-10-24 |
The Broad Institute, Inc. |
Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
|
EP3808766A1
(en)
|
2019-10-15 |
2021-04-21 |
Sangamo Therapeutics France |
Chimeric antigen receptor specific for interleukin-23 receptor
|
CN115894606A
(zh)
|
2019-11-04 |
2023-04-04 |
锐新医药公司 |
Ras抑制剂
|
MX2022005360A
(es)
|
2019-11-04 |
2022-06-02 |
Revolution Medicines Inc |
Inhibidores de ras.
|
CA3159559A1
(en)
|
2019-11-04 |
2021-05-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
EP4054622A1
(en)
|
2019-11-05 |
2022-09-14 |
Celgene Corporation |
Uses of anti-bcma chimeric antigen receptors
|
BR112022008858A2
(pt)
|
2019-11-08 |
2022-09-06 |
Revolution Medicines Inc |
Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer
|
CA3159387A1
(en)
|
2019-11-08 |
2021-05-14 |
Kiyatec, Inc. |
Methods of screening to determine effective dosing of cancer therapeutics
|
EP4058561A1
(en)
|
2019-11-12 |
2022-09-21 |
A2 Biotherapeutics, Inc. |
Engineered t cell receptors and uses thereof
|
WO2021108661A2
(en)
|
2019-11-26 |
2021-06-03 |
Novartis Ag |
Chimeric antigen receptors and uses thereof
|
CA3162892A1
(en)
|
2019-11-26 |
2021-06-03 |
Novartis Ag |
Cd19 and cd22 chimeric antigen receptors and uses thereof
|
US20230029341A1
(en)
|
2019-12-11 |
2023-01-26 |
A2 Biotherapeutics, Inc. |
Nucleic acid encoding lilrb1-based chimeric antigen receptor
|
WO2021130250A1
(en)
|
2019-12-23 |
2021-07-01 |
Cellectis |
New mesothelin specific chimeric antigen receptors (car) for solid tumors cancer immunotherapy
|
CN113025570A
(zh)
*
|
2019-12-24 |
2021-06-25 |
华东数字医学工程研究院 |
一种t细胞增殖方法及其用途
|
US11865168B2
(en)
|
2019-12-30 |
2024-01-09 |
Massachusetts Institute Of Technology |
Compositions and methods for treating bacterial infections
|
CA3163703A1
(en)
|
2020-01-07 |
2021-07-15 |
Steve Kelsey |
Shp2 inhibitor dosing and methods of treating cancer
|
JP2023511274A
(ja)
|
2020-01-14 |
2023-03-17 |
シンセカイン インコーポレイテッド |
Il2オルソログおよび使用法
|
CA3165036A1
(en)
|
2020-01-17 |
2021-07-22 |
Jonathan Alexander Terrett |
Genetically engineered t cells expressing bcma-specific chimeric antigen receptors and uses thereof in cancer therapy
|
EP4093753A1
(en)
|
2020-01-24 |
2022-11-30 |
Regeneron Pharmaceuticals, Inc. |
Preferentially expressed antigen in melanoma (prame) t cell receptors and methods of use thereof
|
US11851445B2
(en)
|
2020-01-29 |
2023-12-26 |
Foghorn Therapeutics Inc. |
Compounds and uses thereof
|
JP2021122748A
(ja)
*
|
2020-02-07 |
2021-08-30 |
マイセル・テクノロジーズ,インコーポレイテッド |
生分解性層を有するステント
|
US20230111593A1
(en)
|
2020-02-14 |
2023-04-13 |
Novartis Ag |
Method of predicting response to chimeric antigen receptor therapy
|
JP2023527609A
(ja)
|
2020-02-21 |
2023-06-30 |
ハープーン セラピューティクス,インク. |
Flt3結合タンパク質および使用方法
|
IL295878A
(en)
|
2020-02-27 |
2022-10-01 |
Novartis Ag |
Methods for producing cells expressing a chimeric antigen receptor
|
WO2021176373A1
(en)
|
2020-03-03 |
2021-09-10 |
Janssen Biotech, Inc. |
ꝩδ T CELLS AND USES THEREOF
|
IL296103A
(en)
|
2020-03-05 |
2022-11-01 |
Neotx Therapeutics Ltd |
Methods and preparations for treating cancer with immune cells
|
EP4114860A1
(en)
|
2020-03-06 |
2023-01-11 |
Go Therapeutics, Inc. |
Anti-glyco-cd44 antibodies and their uses
|
AU2021237790A1
(en)
|
2020-03-20 |
2022-10-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Chimeric antigen receptor specific for human CD45RC and uses thereof
|
CN115916963A
(zh)
|
2020-03-27 |
2023-04-04 |
门德斯有限公司 |
白血病来源的经修饰细胞用于增强过继性细胞治疗的效力的离体用途
|
AU2021256053A1
(en)
|
2020-04-17 |
2022-11-10 |
City Of Hope |
FLT3-targeted chimeric antigen receptor modified cells for treatment of FLT3-positive malignancies
|
WO2021222576A1
(en)
|
2020-05-01 |
2021-11-04 |
A2 Biotherapeutics, Inc. |
Pag1 fusion proteins and methods of making and using same
|
CA3175491A1
(en)
|
2020-05-05 |
2021-11-11 |
David DILILLO |
Car comprising cd28 zeta and cd3 zeta
|
WO2021252635A1
(en)
|
2020-06-11 |
2021-12-16 |
A2 Biotherapeutics, Inc. |
Compositions and methods for treating cancers
|
AU2021288224A1
(en)
|
2020-06-11 |
2023-01-05 |
Novartis Ag |
ZBTB32 inhibitors and uses thereof
|
KR20230042600A
(ko)
|
2020-06-18 |
2023-03-28 |
레볼루션 메디슨즈, 인크. |
Ras 억제제에 대한 획득된 저항성을 지연, 예방, 및 치료하는 방법
|
WO2022016114A1
(en)
|
2020-07-17 |
2022-01-20 |
Instill Bio (Uk) Limited |
Chimeric molecules providing targeted costimulation for adoptive cell therapy
|
JP2023534808A
(ja)
|
2020-07-17 |
2023-08-14 |
インスティル バイオ (ユーケイ) リミテッド |
養子細胞療法のための標的共刺激を提供する受容体
|
US20220023346A1
(en)
|
2020-07-21 |
2022-01-27 |
Allogene Therapeutics, Inc. |
Chimeric antigen receptors with enhanced signaling and activities and uses thereof
|
EP4185616A1
(en)
|
2020-07-24 |
2023-05-31 |
Cellectis S.A. |
T-cells expressing immune cell engagers in allogenic settings
|
US11787800B2
(en)
|
2020-07-29 |
2023-10-17 |
Foghorn Therapeutics Inc. |
BRD9 degraders and uses thereof
|
KR20230042753A
(ko)
|
2020-08-05 |
2023-03-29 |
드래곤플라이 쎄라퓨틱스, 인크. |
Egfr을 표적화하는 항체 및 그의 용도
|
US20230330227A1
(en)
|
2020-08-13 |
2023-10-19 |
A2 Biotherapeutics, Inc. |
Gene fusions for control of genetically modified cells
|
CN116113689A
(zh)
|
2020-08-14 |
2023-05-12 |
凯德药业股份有限公司 |
改善免疫细胞功能
|
WO2022040444A1
(en)
|
2020-08-20 |
2022-02-24 |
A2 Biotherapeutics, Inc. |
Compositions and methods for treating egfr positive cancers
|
IL300497A
(en)
|
2020-08-20 |
2023-04-01 |
A2 Biotherapeutics Inc |
Compositions and methods for treating CEACAM-positive cancer
|
CA3188862A1
(en)
|
2020-08-20 |
2022-02-24 |
Carl Alexander Kamb |
Compositions and methods for treating mesothelin positive cancers
|
US20230321242A1
(en)
|
2020-08-24 |
2023-10-12 |
Charité - Universitätsmedizin Berlin |
Chimeric antigen receptor (car)-expressing cells recognizing cea
|
EP4199959A1
(en)
|
2020-08-24 |
2023-06-28 |
Charité - Universitätsmedizin Berlin |
A chimeric antigen receptor construct encoding a checkpoint inhibitory molecule and an immune stimulatory cytokine and car-expressing cells recognizing cd44v6
|
US11690915B2
(en)
|
2020-09-15 |
2023-07-04 |
Revolution Medicines, Inc. |
Ras inhibitors
|
WO2022058640A1
(es)
|
2020-09-21 |
2022-03-24 |
Fundación Pública Andaluza Progreso Y Salud |
Polinucleótido para expresión fisiológica en células t
|
US20220090013A1
(en)
|
2020-09-21 |
2022-03-24 |
A2 Biotherapeutics, Inc. |
Engineering immune cells based on antigen levels
|
EP4176048A1
(en)
|
2020-09-23 |
2023-05-10 |
CRISPR Therapeutics AG |
Genetically engineered t cells with regnase-1 and/or tgfbrii disruption have improved functionality and persistence
|
EP4241278A2
(en)
|
2020-11-04 |
2023-09-13 |
Celgene Corporation |
Car t cell therapy in patients who have had prior anti-cancer alkylator therapy
|
JP2023547520A
(ja)
|
2020-11-05 |
2023-11-10 |
メンドゥス・ベスローテン・フェンノートシャップ |
免疫療法における腫瘍非依存性抗原の使用
|
WO2022104061A1
(en)
|
2020-11-13 |
2022-05-19 |
Novartis Ag |
Combination therapies with chimeric antigen receptor (car)-expressing cells
|
US20240016936A1
(en)
|
2020-12-04 |
2024-01-18 |
Celgene Corporation |
Uses of chimeric antigen receptor (car) t-cell therapies in combination with inhibitors of inflammation-related soluble factors
|
EP4263600A1
(en)
|
2020-12-18 |
2023-10-25 |
Century Therapeutics, Inc. |
Chimeric antigen receptor systems with adaptable receptor specificity
|
KR20230122618A
(ko)
|
2020-12-21 |
2023-08-22 |
알로젠 테라퓨틱스 인코포레이티드 |
프로테아제 활성화 cd45-게이트 car
|
AU2021409816A1
(en)
|
2020-12-22 |
2023-07-06 |
Qilu Regor Therapeutics Inc. |
Sos1 inhibitors and uses thereof
|
US20240041927A1
(en)
|
2020-12-22 |
2024-02-08 |
Deutsches Zentrum Für Neurodegenerative Erkrankungen E. V. (Dzne) |
Chimeric autoantibody receptor (caar) comprising a nicotinic acetylcholine receptor autoantigen
|
EP4019538A1
(en)
|
2020-12-22 |
2022-06-29 |
Charité - Universitätsmedizin Berlin |
Reprogramming immune cells by targeted integration of zeta-deficient chimeric antigen receptor transgenes
|
WO2022137186A1
(en)
|
2020-12-23 |
2022-06-30 |
Crispr Therapeutics Ag |
Cancer treatment using cd38 inhibitor and/or lenalidomide and t-cells expressing a chimeric antigen receptor
|
WO2022137181A1
(en)
|
2020-12-23 |
2022-06-30 |
Crispr Therapeutics Ag |
Co-use of lenalidomide with car-t cells
|
WO2022136681A1
(en)
|
2020-12-23 |
2022-06-30 |
Gadeta B.V. |
Chimeric, transmembrane proteins with bidirectional signalling activity
|
JP2024502599A
(ja)
|
2021-01-10 |
2024-01-22 |
カイト ファーマ インコーポレイテッド |
T細胞療法
|
WO2022164959A1
(en)
|
2021-01-27 |
2022-08-04 |
Lyell Immunopharma, Inc. |
Improved immune cell therapy
|
US20220249556A1
(en)
|
2021-01-28 |
2022-08-11 |
Allogene Therapeutics, Inc. |
Methods for transducing immune cells
|
US20220233690A1
(en)
|
2021-01-28 |
2022-07-28 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for treating cytokine release syndrome
|
JP2024505075A
(ja)
|
2021-01-29 |
2024-02-02 |
アロジーン セラピューティクス,インコーポレイテッド |
同種細胞産物のT細胞認識を軽減するための、TAP2、NLRC5、β2m、TRAC、RFX5、RFXAP及びRFXANKのうち1つ以上のノックダウン又はノックアウト
|
CA3207958A1
(en)
|
2021-02-16 |
2022-08-25 |
Julyun OH |
Compositions and methods for treating her2 positive cancers
|
WO2022178243A1
(en)
|
2021-02-20 |
2022-08-25 |
Kite Pharma, Inc. |
Gene markers for sellecting immunotherapies
|
EP4301772A1
(en)
|
2021-03-04 |
2024-01-10 |
Allogene Therapeutics, Inc. |
Fasl expression and fasr gene knockout to protect therapeutic cells from allogeneic rejection and activation-induced cell death
|
EP4301782A1
(en)
|
2021-03-05 |
2024-01-10 |
Go Therapeutics, Inc. |
Anti-glyco-cd44 antibodies and their uses
|
US20220288122A1
(en)
|
2021-03-09 |
2022-09-15 |
Crispr Therapeutics Ag |
Genetically engineered t cells with ptpn2 knockout have improved functionality and anti-tumor activity
|
IL305571A
(en)
|
2021-03-11 |
2023-10-01 |
Kite Pharma Inc |
Improving the function of immune system cells
|
JP2024513453A
(ja)
|
2021-04-08 |
2024-03-25 |
ヤンセン バイオテツク,インコーポレーテツド |
増強された幹細胞様メモリーt細胞操作のための材料及び方法
|
KR20230171994A
(ko)
|
2021-04-16 |
2023-12-21 |
셀진 코포레이션 |
선행 줄기 세포 이식을 받은 환자에서의 t 세포 요법
|
EP4330288A1
(en)
|
2021-04-30 |
2024-03-06 |
Cellectis S.A. |
New anti-muc1 cars and gene edited immune cells for solid tumors cancer immunotherapy
|
BR112023023067A2
(pt)
|
2021-05-04 |
2024-01-30 |
Regeneron Pharma |
Receptores de antigénios quiméricos com especificidade mage-a4 e usos dos mesmos
|
PE20240089A1
(es)
|
2021-05-05 |
2024-01-16 |
Revolution Medicines Inc |
Inhibidores de ras para el tratamiento del cancer
|
BR112023022819A2
(pt)
|
2021-05-05 |
2024-01-16 |
Revolution Medicines Inc |
Compostos, composição farmacêutica, conjugados e métodos para tratar câncer em um sujeito, para tratar um distúrbio e para inibir uma proteína ras em uma célula
|
US20240207319A1
(en)
|
2021-05-06 |
2024-06-27 |
Ludwig Institute For Cancer Research Ltd |
Compositions and methods for immunotherapy
|
AR125852A1
(es)
|
2021-05-12 |
2023-08-16 |
Crispr Therapeutics Ag |
Células inmunes modificadas genéticamente que se focalizan en cd70 para su uso en tratamiento de tumores sólidos
|
WO2022238962A1
(en)
|
2021-05-12 |
2022-11-17 |
Crispr Therapeutics Ag |
Genetically engineered immune cells targeting cd70 for use in treating hematopoietic malignancies
|
IL308227A
(en)
|
2021-05-14 |
2024-01-01 |
Kite Pharma Inc |
T-cell chemical antigen receptor therapy
|
CA3217668A1
(en)
|
2021-05-20 |
2022-11-24 |
Toni CATHOMEN |
Gene therapy for the treatment of hyper-ige syndrome (hies) by targeted gene integration
|
EP4341300A1
(en)
|
2021-05-21 |
2024-03-27 |
Cellectis S.A. |
Enhancing efficacy of t-cell-mediated immunotherapy by modulating cancer-associated fibroblasts in solid tumors
|
TW202307210A
(zh)
|
2021-06-01 |
2023-02-16 |
瑞士商諾華公司 |
Cd19和cd22嵌合抗原受體及其用途
|
BR112023022097A2
(pt)
|
2021-06-07 |
2023-12-19 |
Agonox Inc |
Cxcr5, pd-1 e icos expressando células t cd4 reativas de tumor e seu uso
|
EP4355358A1
(en)
|
2021-06-15 |
2024-04-24 |
Allogene Therapeutics, Inc. |
Selective targeting of host cd70+ alloreactive cells to prolong allogeneic car t cell persistence
|
US11945876B2
(en)
|
2021-06-16 |
2024-04-02 |
Instil Bio (Uk) Limited |
Receptors providing targeted costimulation for adoptive cell therapy
|
EP4363059A1
(en)
|
2021-06-29 |
2024-05-08 |
Flagship Pioneering Innovations V, Inc. |
Immune cells engineered to promote thanotransmission and uses thereof
|
US11767330B2
(en)
|
2021-07-06 |
2023-09-26 |
Foghorn Therapeutics Inc. |
Citrate salt, pharmaceutical compositions, and methods of making and using the same
|
CN117980326A
(zh)
|
2021-07-14 |
2024-05-03 |
2赛文缇生物公司 |
与来自抗体的结合结构域融合的经工程化的t细胞受体
|
WO2023288278A1
(en)
|
2021-07-16 |
2023-01-19 |
Instil Bio (Uk) Limited |
Chimeric molecules providing targeted costimulation for adoptive cell therapy
|
EP4376873A1
(en)
|
2021-07-26 |
2024-06-05 |
CRISPR Therapeutics AG |
Methods for manufacturing genetically engineered car-t cells
|
IL310550A
(en)
|
2021-08-04 |
2024-03-01 |
Univ Colorado Regents |
LAT-activating chimeric antigen receptor T cells and methods of using them
|
EP4380604A1
(en)
|
2021-08-05 |
2024-06-12 |
Go Therapeutics, Inc. |
Anti-glyco-muc4 antibodies and their uses
|
AU2022327766A1
(en)
|
2021-08-13 |
2023-12-14 |
Ludwig-Maximilians-Universität München |
Anti-csf1r car expressing lymphocytes for targeted tumor therapy
|
WO2023021113A1
(en)
|
2021-08-18 |
2023-02-23 |
Julius-Maximilians-Universität Würzburg |
Hybrid tumor/cancer therapy based on targeting the resolution of or inducing transcription-replication conflicts (trcs)
|
MX2024002436A
(es)
|
2021-08-24 |
2024-06-03 |
Ecole Polytechnique Fed De Lausanne Epfl |
Celulas que expresan il-10 para inmunoterapias mejoradas contra el cancer.
|
EP4396232A1
(en)
|
2021-09-03 |
2024-07-10 |
Go Therapeutics, Inc. |
Anti-glyco-lamp1 antibodies and their uses
|
TW202328188A
(zh)
|
2021-09-03 |
2023-07-16 |
美商Go治療公司 |
抗醣化-cmet抗體及其用途
|
US20230128917A1
(en)
|
2021-09-14 |
2023-04-27 |
Crispr Therapeutics Ag |
Genetically engineered immune cells having a disrupted cd83 gene
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
WO2023081813A1
(en)
|
2021-11-05 |
2023-05-11 |
St. Jude Children's Research Hospital, Inc. |
Zip cytokine receptors
|
WO2023081894A2
(en)
|
2021-11-08 |
2023-05-11 |
St. Jude Children's Research Hospital, Inc. |
Pre-effector car-t cell gene signatures
|
WO2023084399A1
(en)
|
2021-11-09 |
2023-05-19 |
Crispr Therapeutics Ag |
Genetically engineered immune cells expressing masked chimeric antigen receptors specific to protein tyrosine kinase 7
|
WO2023092119A2
(en)
|
2021-11-22 |
2023-05-25 |
Ludwig Institute For Cancer Research Ltd |
Methods for predicting responsiveness to a cancer therapy
|
WO2023107954A1
(en)
|
2021-12-08 |
2023-06-15 |
Dragonfly Therapeutics, Inc. |
Antibodies targeting 5t4 and uses thereof
|
WO2023111913A1
(en)
|
2021-12-15 |
2023-06-22 |
Crispr Therapeutics Ag |
Engineered anti-liv1 cell with regnase-1 and/or tgfbrii disruption
|
TW202340214A
(zh)
|
2021-12-17 |
2023-10-16 |
美商健臻公司 |
做為shp2抑制劑之吡唑并吡𠯤化合物
|
WO2023119201A2
(en)
|
2021-12-22 |
2023-06-29 |
Crispr Therapeutics Ag |
Genetically engineered t cells with disrupted casitas b-lineage lymphoma proto-oncogene-b (cblb) and uses thereof
|
WO2023150181A1
(en)
|
2022-02-01 |
2023-08-10 |
President And Fellows Of Harvard College |
Methods and compositions for treating cancer
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
US20230296610A1
(en)
|
2022-02-15 |
2023-09-21 |
Kite Pharma, Inc. |
Predicting adverse events from immunotherapy
|
WO2023172940A1
(en)
|
2022-03-08 |
2023-09-14 |
Revolution Medicines, Inc. |
Methods for treating immune refractory lung cancer
|
WO2023170606A1
(en)
|
2022-03-08 |
2023-09-14 |
Alentis Therapeutics Ag |
Use of anti-claudin-1 antibodies to increase t cell availability
|
WO2023180968A1
(en)
|
2022-03-23 |
2023-09-28 |
Crispr Therapeutics Ag |
Anti-cd19 car-t cells with multiple gene edits and therapeutic uses thereof
|
WO2023180967A1
(en)
|
2022-03-23 |
2023-09-28 |
Crispr Therapeutics Ag |
Anti-cd83 car-t cells with regnase-1 and/or tgfbrii disruption
|
US20230346934A1
(en)
|
2022-03-29 |
2023-11-02 |
Allogene Therapeutics, Inc. |
Chimeric switch receptors for the conversion of immunesuppressive signals to costimulatory signals
|
WO2023196921A1
(en)
|
2022-04-06 |
2023-10-12 |
The Regents Of The University Of Colorado, A Body Corporate |
Granzyme expressing t cells and methods of use
|
WO2023196933A1
(en)
|
2022-04-06 |
2023-10-12 |
The Regents Of The University Of Colorado, A Body Corporate |
Chimeric antigen receptor t cells and methods of use thereof
|
WO2023196996A2
(en)
|
2022-04-08 |
2023-10-12 |
2Seventy Bio, Inc. |
Multipartite receptor and signaling complexes
|
EP4276174A1
(en)
|
2022-05-09 |
2023-11-15 |
Cellectis S.A. |
Gene therapy for the treatment of activated pi3kinase delta syndrome type 1 (apds1)
|
WO2023220644A1
(en)
|
2022-05-10 |
2023-11-16 |
Yale University |
Compositions and methods of synthetic ctla-4 tails for reprogramming of car-t cells and enhancement of anti-tumor efficacy
|
WO2023220641A2
(en)
|
2022-05-11 |
2023-11-16 |
Juno Therapeutics, Inc. |
Methods and uses related to t cell therapy and production of same
|
WO2023230548A1
(en)
|
2022-05-25 |
2023-11-30 |
Celgene Corporation |
Method for predicting response to a t cell therapy
|
WO2023230512A1
(en)
|
2022-05-26 |
2023-11-30 |
2Seventy Bio, Inc. |
Compositions for maintaining lentiviral vector and uses thereof
|
WO2023240182A1
(en)
|
2022-06-08 |
2023-12-14 |
St. Jude Children's Research Hospital, Inc. |
Disruption of kdm4a in t cells to enhance immunotherapy
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
WO2023242434A1
(en)
|
2022-06-17 |
2023-12-21 |
Gadeta B.V. |
Modified immune cells
|
WO2023248110A1
(en)
|
2022-06-20 |
2023-12-28 |
Crispr Therapeutics Ag |
Base editing proteins and uses thereof
|
WO2024003786A1
(en)
|
2022-06-29 |
2024-01-04 |
Crispr Therapeutics Ag |
Chimeric antigen receptor targeting gpc-3 and immune cells expressing such for therapeutic uses
|
WO2024003334A1
(en)
|
2022-06-30 |
2024-01-04 |
Cellectis S.A. |
Enhancing safety of t-cell-mediated immunotherapy
|
WO2024010782A1
(en)
|
2022-07-06 |
2024-01-11 |
Vividion Therapeutics, Inc. |
Pharmaceutical compositions comprising wrn helicase inhibitors
|
TW202408487A
(zh)
|
2022-07-06 |
2024-03-01 |
美商維維迪昂醫療公司 |
包含wrn解旋酶抑制劑之醫藥組成物
|
TW202413646A
(zh)
|
2022-07-22 |
2024-04-01 |
美商萊爾免疫藥物股份有限公司 |
免疫細胞療法
|
WO2024023804A2
(en)
|
2022-07-29 |
2024-02-01 |
Crispr Therapeutics Ag |
Genetically engineered immune cells having disrupted transporter associated with antigen processing binding protein (tapbp) gene
|
WO2024023802A2
(en)
|
2022-07-29 |
2024-02-01 |
Crispr Therapeutics Ag |
Genetically engineered immune cells having disrupted transporter associated with antigen processing-2 (tap-2) gene
|
WO2024023801A2
(en)
|
2022-07-29 |
2024-02-01 |
Crispr Therapeutics Ag |
Genetically engineered immune cells having disrupted transporter associated with antigen processing-1 (tap-1) gene
|
WO2024026445A1
(en)
|
2022-07-29 |
2024-02-01 |
Allogene Therapeutics Inc. |
Engineered cells with reduced gene expression to mitigate immune cell recognition
|
WO2024030441A1
(en)
|
2022-08-02 |
2024-02-08 |
National University Corporation Hokkaido University |
Methods of improving cellular therapy with organelle complexes
|
US20240091261A1
(en)
|
2022-08-26 |
2024-03-21 |
Kite Pharma, Inc. |
Immune cell function
|
WO2024056809A1
(en)
|
2022-09-15 |
2024-03-21 |
Novartis Ag |
Treatment of autoimmune disorders using chimeric antigen receptor therapy
|
WO2024059787A1
(en)
|
2022-09-16 |
2024-03-21 |
St. Jude Children's Research Hospital, Inc. |
Disruption of asxl1 in t cells to enhance immunotherapy
|
WO2024062388A2
(en)
|
2022-09-20 |
2024-03-28 |
Crispr Therapeutics Ag |
Genetically engineered immune cells expressing chimeric antigen receptor targeting cd20
|
EP4353253A1
(en)
|
2022-10-10 |
2024-04-17 |
Charité - Universitätsmedizin Berlin |
Purification of tcr-modified t cells using tcr-specific car-nk cells
|
EP4353252A1
(en)
|
2022-10-10 |
2024-04-17 |
Charité - Universitätsmedizin Berlin |
Antigen-specific t cells by gene editing of cd3 epsilon
|
WO2024081736A2
(en)
|
2022-10-11 |
2024-04-18 |
Yale University |
Compositions and methods of using cell-penetrating antibodies
|
WO2024092092A2
(en)
|
2022-10-27 |
2024-05-02 |
Cargo Therapeutics, Inc. |
Compositions and methods for allogeneic immunotherapies
|
WO2024092152A1
(en)
|
2022-10-28 |
2024-05-02 |
Kite Pharma, Inc. |
Improving efficacy and durable response of immunotherapy
|
WO2024091669A1
(en)
|
2022-10-28 |
2024-05-02 |
Ginkgo Bioworks, Inc. |
Chimeric antigen receptors comprising an intracellular domain pair
|
TW202417643A
(zh)
|
2022-10-28 |
2024-05-01 |
美商凱特製藥公司 |
用於將免疫療法最佳化之因素
|
WO2024097642A1
(en)
|
2022-10-31 |
2024-05-10 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating cancer with a combination of adoptive cell therapy and a targeted immunocytokine
|
WO2024094775A1
(en)
|
2022-11-03 |
2024-05-10 |
Cellectis S.A. |
Enhancing efficacy and safety of t-cell-mediated immunotherapy
|
US20240216430A1
(en)
|
2022-11-28 |
2024-07-04 |
Allogene Therapeutics, Inc. |
Claudin 18.2 targeting chimeric antigen receptors and binding agents and uses thereof
|
WO2024119074A1
(en)
|
2022-12-01 |
2024-06-06 |
Generation Bio Co. |
Stealth lipid nanoparticle compositions for cell targeting
|
WO2024124044A1
(en)
|
2022-12-07 |
2024-06-13 |
The Brigham And Women’S Hospital, Inc. |
Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
|
WO2024155821A1
(en)
|
2023-01-18 |
2024-07-25 |
Yale University |
Chimeric antigen receptors (car) with intrinsically disordered regions and methods of use thereof
|
WO2024160845A1
(en)
|
2023-01-30 |
2024-08-08 |
Ludwig-Maximilians-Universität München |
Anti-cd86 car expressing lymphocytes for targeted tumor therapy
|